169 results about "Liver lipid" patented technology

The invention relates to a biological preparation for improving quality of weever, the biological preparation comprises an injection and an edible agent, the injection comprises chemically modified chemically synthesized single-stranded small RNA, Rev-erbalpha protein and Per1 protein, and the edible agent comprises Clock core peptide 1, Clock core peptide 2 and taurine. Skeletal muscle development, liver lipid metabolism and generation of cell inflammatory factors of the weever are influenced by adding and injecting the feed, so that the quality of the weever is improved, intramuscular fat deposition is promoted, the taste and flavor of fish meat are improved, the energy reserve of the weever can be improved, and the culture cycle is shortened. The improvement of cell inflammatory factors shows that the disease resistance of the weever is improved, the survival rate in the breeding process is further improved, and the use amount of antibiotics is reduced. The method provides an important theoretical basis for improving fish meat quality in China and promoting high-quality, efficient and healthy development of aquaculture, and has a wide market prospect.

The invention relates to pediococcus acidilactici XZ106, which is classified and named as pediococcus acidilactici, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30094, the preservation date is March 22, 2024, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The pediococcus acidilactici XZ106 can (1) relieve insulin resistance, regulate insulin and glucagon secretion and improve liver gluconeogenesis, so that diabetes hyperglycemia is improved; (2) weight gain, fat accumulation and liver lipid accumulation of obese mice are inhibited, glycolipid metabolism disorder of the mice is improved, and the composition has excellent effects of reducing fat and relieving obesity; (3) the level of IL-10 can be remarkably improved, and the anti-inflammatory ability of mice is improved; (4) vascular injury is reduced, so that diabetic complications and various cardiovascular diseases of atherosclerosis are prevented.

The invention discloses a lactobacillus plantarum strain from healthy people in a cold region and application of the lactobacillus plantarum strain. The lactobacillus plantarum strain is named as PL-H1, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.22286. The lactobacillus plantarum PL-H1 screened by the invention can obviously relieve the disease index, intestinal canal pathological change, inflammatory response and the like of an inflammatory bowel disease (IBD) model mouse. Moreover, compared with a standard strain WCSF1, the strain has the high metabolism characteristic of tryptophan and the function of adjusting the metabolism of IBD host intestinal tryptophan, and the curative effect of preventing and treating IBD is more remarkable. In addition, the lactobacillus plantarum strain PL-H1 can also improve the liver lipid accumulation and NAFLD activity of MCD fed mice, improve the blood lipid level and liver injury of the MCD fed mice and prevent liver fibrosis of the MCD fed mice, can be used for preventing and treating fungal infection related diseases, and is good in safety.

The invention belongs to the field of active peptides, and particularly relates to application of selenium-rich polypeptide in inhibiting NLRP3 inflammasome-related inflammations and regulating cholesterol transport protection lipid metabolism abnormality, the selenium-rich polypeptide is prepared by chelating Adi-Apo fusion protein as shown in SEQ ID NO: 3 and sodium selenite (Na2SeO3); the selenium peptide chelate has the effects of remarkably reducing the concentration of TC / TG in serum, reducing the liver lipid deposition and inflammation level and reducing the atherosclerotic plaque area proportion through high oxidation resistance and high anti-inflammatory activity, and can be used for treating and / or preventing lipid metabolism disorder diseases such as metabolism-related fatty liver diseases and coronary atherosclerosis.

The invention relates to the technical field of microorganisms, in particular to enterococcus faecalis EF-1 capable of reducing blood lipid, a microbial preparation and application of the enterococcus faecalis EF-1. The enterococcus faecalis EF-1 is preserved in the China General Microbiological Culture Collection Center (CGMCC) on September 27, 2024, and the preservation number is CGMCC No.32097. The enterococcus faecalis EF-1 is named as enterococcus faecalis EF-1. The enterococcus faecalis EF-1 has the functions of: (1) relieving the weight increase speed of animals, reducing body weight gain, and preventing, relieving or treating obesity; (2) the contents of triglyceride, cholesterol and low-density lipoprotein cholesterol in liver and serum are reduced; (3) the liver function is protected, and the contents of ALT and AST in serum and liver are reduced; (4) liver lipid deposition and lesion are relieved; (5) relieving adipose tissue hypertrophy; (6) preventing, relieving or treating metabolic syndrome; (7) reducing blood sugar, improving insulin resistance and relieving diabetes mellitus; 8, increasing the content of short-chain fatty acid; and (9) regulating intestinal flora.

The invention relates to the technical field of biotechnology and gene function and application, and provides application of SNHG8 in preparation of drugs for preventing and treating non-alcoholic fatty liver diseases. The medicine is used for preventing and treating the non-alcoholic fatty liver disease by promoting SNHG8 gene expression. The SNHG8 is applied to preparation of the medicine for preventing and treating the non-alcoholic fatty liver disease, the medicine can effectively reduce the content of triglyceride in the liver by promoting SNHG8 gene expression, liver lipid accumulation increase and lipid metabolism related protein expression up-regulation induced by high-fat and high-cholesterol diet are relieved, and therefore the non-alcoholic fatty liver disease is prevented, treated or relieved. The purpose of preventing and treating the non-alcoholic fatty liver disease is achieved.

The invention belongs to the technical field of biological medicine, and particularly relates to application of hUC-MSCs combined with Met in preparation of anti-diabetic drugs. The diabetes mellitus is particularly type 2 diabetes mellitus. Through construction of a T2DM rat model, paraffin tissue section detection, serum ELISA, cell experiments and the like, researches prove that T2DM can be effectively treated by HUC-MSCs combined with Met treatment, including reduction of body blood sugar and recovery of blood sugar regulation ability; liver injury caused by T2DM is relieved and repaired; the glycolipid metabolism of the liver of the T2DM rat is improved; the immune inflammation disorder caused by T2DM is relieved; and the apoptosis level of liver cells is improved. And compared with a single hUC-MSCs or Met treatment mode, the combined treatment mode has a better treatment effect. The invention provides a theoretical basis and a new treatment strategy for treatment of T2DM.

The invention discloses a lactobacillus rhamnosus GYX-9 strain and an application of the lactobacillus rhamnosus GYX-9 strain. The lactobacillus rhamnosus GYX-9 disclosed by the invention can be used for regulating the problems of blood lipid metabolism disorder, liver lipid accumulation or pathological injury and the like caused by high-fat diet. The lactobacillus rhamnosus GYX-9 disclosed by the invention can be used for reducing the level of TNF-alpha, increasing the content of IL-10 and regulating colonic immune disorder; the abundance of intestinal microbiome communities is adjusted; according to the invention, the lactobacillus rhamnosus GYX-9 is combined to regulate and control the metabolic disorder caused by high-fat diet on the basis of'intestinal flora-intestine-liver axis'. The normal-temperature viable bacterium fermented milk with the viable bacterium number not less than 108 cfu / mL is also prepared, the normal-temperature viable bacterium fermented milk has remarkable capabilities of lowering cholesterol, combining taurocholate and inhibiting pancreatic lipase, and the pancreatic lipase inhibition rate can reach 67.06%.

The invention discloses a Coprococcus eutaxus strain and an application of the Coprococcus eutaxus strain, and relates to the technical field of probiotics. According to the present invention, the Coprococcus eutactus strain is named as Coprococcus eutactus GZSY125, the preservation number is CGMCC No.66029, the preservation date is March 18, 2025, the preservation classification is named as Coprococcus eutactus, the preservation unit is Guangdong Microbial Culture Collection Center, and the address of the preservation unit is the fifth floor, No. 59 building, No. 100 Courtyard, Xianlie Middle Road, Guangdong Province, the preservation number is CGMCC No.66029, the preservation number is CGMCC No.66029, the preservation date is March 18, 2025, the preservation classification is named as Coprococcus eutactus, and the preservation number is CGMCC No.66029. The invention provides the Coprococcus eutaxus, the Coprococcus eutaxus can be used for remarkably improving liver lipid accumulation, inflammation and fibrosis, has a certain treatment effect on the metabolism-related fatty liver disease (MAFLD), provides a new treatment thought for clinically intervening the MAFLD, and has important clinical significance on the treatment of the MAFLD.

The invention provides a preparation method of probiotic fermented polygonatum sibiricum polysaccharide, and belongs to the field of traditional Chinese medicinal material processing. The preparation method comprises the following steps: (1) adding cellulase and pectinase into polygonatum kingianum, carrying out water extraction, carrying out enzyme deactivation after water extraction, and carrying out suction filtration to obtain filtrate; (2) preparing bacillus DU-106 and lactobacillus plantarum nbk-MA2 into bacterial powder, and adding water to obtain bacterial liquid; mixing the bacterial liquid with the filtrate, fermenting, performing suction filtration, and centrifuging to obtain supernate; performing alcohol precipitation to remove protein; carrying out ethanol precipitation by using absolute ethyl alcohol again, collecting the precipitate after centrifuging, and carrying out redissolution, dialysis and freeze-drying to obtain fermentation modified crude polysaccharide; and (3) purifying the fermented and modified crude polysaccharide to obtain a purified polysaccharide component. The obtained probiotic fermented polygonatum sibiricum polysaccharide has the effect of losing weight, and can obviously improve the obesity characteristics of mice, specifically, reducing body weight, reducing fat, reducing serum liver lipid level, relieving serum liver inflammation of the mice, weakening blood glucose insulin sensitivity, repairing liver injury and the like.

The invention discloses application of 2-hydroxybutyric acid and derivatives thereof in preparation of drugs for preventing and / or treating metabolic diseases, and belongs to the technical field of biological medicines. Experiments prove that the 2-hydroxybutyric acid and the derivatives thereof can effectively inhibit obesity induced by high fat diet and reduce body fat, and have good improvement effects on related glucose and lipid metabolism disorders, including reduction of fasting blood-glucose, improvement of glucose tolerance, reduction of liver lipid deposition and improvement of liver functions. More importantly, the 2-hydroxybutyric acid does not affect ingestion, the metabolism improvement effect of the 2-hydroxybutyric acid depends on activation of fat heat production, and energy consumption can be directly promoted, so that obvious gastrointestinal tract adverse reactions cannot be generated, and potential mental side effects of existing appetite inhibiting drugs do not exist.

The invention belongs to the technical field of biological medicine, and particularly relates to application of antifreeze protein in weight losing and blood sugar reducing. The NPAFP transgenic mouse model is successfully constructed by utilizing a genetic engineering technology, and the potential application value of the NPAFP protein in weight loss and blood sugar reduction is verified. Furthermore, based on the model, it is found that the NPAFP protein has remarkable effects in the aspects of reducing fat accumulation and improving the blood glucose level by adjusting brown fat metabolism and the liver lipid droplet content. Based on compound development or protein engineering modification of the NPAFP protein, novel drugs and strategies can be provided for treatment of obesity and diabetes mellitus. Meanwhile, the molecular mechanism of the NPAFP protein is further explored by combining a multi-omics technology, and clinical transformation and application of the NPAFP protein are promoted.

The invention provides a salix soongarica flower extract and application thereof in preparation of weight-losing products, and belongs to the technical field of extraction of effective components of Chinese herbal medicines. According to the present invention, the product extracted from the soongarica soongarica flower through 70% alcohol and subjected to rotary evaporation concentration has effects of high fat diet induced animal weight reducing, liver lipid accumulation improving and liver inflammation improving, can be used for preparing the fat reducing product, and has good market application prospects.

The invention discloses an FAM20B protein and application of an FAM20B protein inhibitor in prevention or treatment of glucolipid metabolism related diseases. Specifically, the invention discloses an application of an FAM20B protein and / or an FAM20B gene in regulation and control of liver glycolipid metabolism. The invention also discloses application of the FAM20B inhibitor in improving, preventing or treating liver glycolipid metabolism disorder or glycolipid metabolism related diseases (such as diabetes, metabolism related fatty liver disease MAFLD, obesity and the like). Experiments show that the FAM20B inhibitor can reduce the liver gluconeogenesis level, relieve impairment of glucose tolerance, relieve hyperglycemia of diabetic patients, reduce the fat content of the whole body and the liver, relieve liver lipid deposition, promote energy consumption, reduce food intake, promote fat burning and reduce liver fat accumulation; the compound can be used for preparing medicines for preventing and treating glucose and lipid metabolism disorder or glucose and lipid metabolism related diseases, and has a wide application prospect in the fields of prevention and treatment of metabolism related diseases.

The invention mainly relates to a composition for reducing fat and losing weight as well as a preparation method and application thereof, and belongs to the technical field of biology. The composition comprises 30-60 parts of cordyceps flower sporocarp particles, 5-20 parts of morchella sporocarp particles, 10-25 parts of tartary buckwheat powder, 10-25 parts of a mulberry leaf water extract, 5-21 parts of a rhizoma polygonati water extract and 1-6 parts of a cassia seed water extract. The raw materials are mixed to obtain the composition. The composition can improve the blood fat level of hyperlipidemia, inhibit weight increase, reduce the volume of white fat cells, inhibit liver lipid deposition, reverse liver tissue and liver function damage, effectively reduce lipid and lose weight, and play a role in treating hyperlipidemia, obesity and fatty liver.

The present invention relates to the field of biomedicine technology, and provides the use of an upregulator of ACOT2 in promoting liver regeneration and liver function recovery after partial hepatectomy. Specifically, it provides the use of an ACOT2 expression promoter in the preparation of a drug for promoting liver regeneration and liver function recovery after partial hepatectomy, as well as a pharmaceutical composition comprising the ACOT2 expression promoter. The present invention has developed new discoveries about the function of the ACOT2 gene. The increased expression of ACOT2 after hepatectomy has a certain protective effect on liver regeneration, or can serve as a potential marker for warning the degree of postoperative liver function damage and liver regeneration capacity, and a therapeutic target for promoting postoperative liver regeneration. By using the intervention method of the present invention, the decomposition and consumption of lipid droplets in the liver lipid metabolism process are targeted, thereby promoting the recovery of liver function and liver-to-body ratio.

The invention relates to the field of traditional Chinese medicine preparations, in particular to a traditional Chinese medicine composition for treating non-alcoholic fatty liver, a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition to treatment of the non-alcoholic fatty liver. The traditional Chinese medicine composition is composed of artemisia capillaries, rhizoma anemones raddeanae, fructus gardeniae and rheum officinale. Artemisia capillaris is used as a monarch drug and has the effects of clearing heat, promoting diuresis, benefiting gallbladder and removing jaundice; the two head hairs and the fructus gardeniae are used as ministerial drugs, the former drugs clear away heat and toxic materials, relieve pain and regulate liver lipid metabolism, and the latter drugs purge fire, relieve restlessness, clear heat and promote diuresis; rheum officinale is used as an assistant and guide drug and has the effects of purging heat, removing stasis and relaxing bowels. All the components have a synergistic effect and jointly exert the effect of treating NAFLD.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a duochin in preparation of a medicine for treating MASLD. The research finds that the eriochin has a positive effect on treatment of MASLD, and can effectively delay the body weight, liver weight and liver weight-body weight ratio of MASLD mice, relieve liver injury, relieve liver lipid deposition, liver fatty degeneration, inflammation and fibrosis and delay the MASLD disease progress. Research finds that the eriochin can effectively reduce body weight, relieve liver injury and relieve fatty degeneration and inflammation of the liver, so that MASLD is improved. The invention provides a new thought for the treatment research of MASLD.

The invention discloses application of a substance taking MANF as a target spot in preparation of a medicine for treating non-alcoholic steatohepatitis. The research finds that the expression of the MANF in liver tissues of a fatty liver patient and a non-alcoholic steatohepatitis model mouse is obviously up-regulated, and the weight, liver lipid accumulation and inflammatory infiltration of the NASH mouse can be obviously reduced by specifically knocking out the MANF by the macrophage, so that the MANF in the macrophage plays an important role in the NASH pathological process.

The invention discloses liquiritigenin and isoliquiritigenin produced by directionally converting liquiritin and isoliquiritigenin through lactobacillus plantarum CCFM1275 and application of the liquiritigenin and the isoliquiritigenin. Researches show that the lactobacillus plantarum CCFM1275 can grow in a fermentation base material rich in a licorice extract, and liquiritin and isoliquiritin in licorice can be converted into liquiritigenin and isoliquiritigenin respectively, so that utilization of active ingredients of liquiritin and isoliquiritigenin by an organism is facilitated, and the effect of the licorice extract is improved. Compared with the licorice root extract, the fermented licorice root postbiotics obtained by fermenting and converting the licorice root extract through the lactobacillus plantarum CCFM1275 can further improve the effects of the licorice root extract in the aspects of reducing liver lipid accumulation, lowering lipid and resisting aging, can be used for preparing products with the effects of preventing and / or treating fatty liver and obesity and / or resisting aging, and has a huge application prospect.

The invention provides a preparation method of an apple water kefir beverage and application of the apple water kefir beverage in lowering cholesterol. The method comprises the following steps: preparing apple juice, activating water kefir grains, inoculating the activated water kefir grains into the apple juice, and fermenting to prepare the apple water kefir beverage. The volatile component change in the fermentation process is analyzed through GC-MS and GC-IMS systems, it is proved that the unique bouquet characteristic and flavor coordination of the apple water kefir beverage are improved through water kefir grain fermentation, and meanwhile the organic acid composition is optimized. A mouse model verifies that the apple water kefir beverage has the effect of reducing cholesterol, can reduce liver lipid droplets, total cholesterol, low-density lipoprotein and triglyceride levels, and also can regulate intestinal microbial communities (increase firmicobacteria, bacteroides and faecalis bacteria). The apple water kefir beverage disclosed by the invention has wide market potential and provides a scientific basis for the development of functional beverages.

The invention provides a non-alcoholic fatty liver disease zebra fish model and a construction method thereof, and relates to the technical field of genetic engineering and molecular biology. The sgRNA of the targeted zebrafish fads2 gene contains a guide sequence which can be specifically combined with a nucleotide sequence shown as SEQ ID NO.4 in the fads2 gene. The sgRNA targeting the fads2 gene of the zebrafish can accurately and efficiently target and knock out the fads2 gene of the zebrafish, so that a non-alcoholic fatty liver model which is caused by DHA (docosahexaenoic acid) deficiency and is represented by liver lipid accumulation is successfully constructed, and the sgRNA is a key technical tool for constructing a specific disease model.

The invention relates to the technical field of health food, in particular to a selenium tea ethanol dehydrogenase activating peptide composition as well as a preparation method and application thereof. A response surface method is adopted to optimize a TSE-PP preparation process, affinity ultrafiltration and LC-MS / MS technologies are utilized to screen ADH binding peptides, and the action mechanism of the ADH binding peptides is researched through molecular docking and animal experiments. Experiments prove that the TSE-PP can promote ethanol metabolism, relieve liver cell injury, inhibit inflammatory response, relieve oxidative stress and improve liver lipid accumulation, the high-dose use effect is more remarkable, and a scientific basis is provided for application of the TSE-PP in the food with the function of dispelling the effects of alcohol and the nutrition fortified product. The invention discloses the preparation process of the TSE-PP and the anti-alcohol and liver protection effects of the TSE-PP, meanwhile, the TSE-PP has good food processing characteristics, and a theoretical basis and an experimental support are provided for production and application of the TSE-PP in functional foods.

The invention relates to application of Ago2 in preparation of medicines for treating fatty liver or hyperlipemia and a product of the Ago2, belonging to the field of biological medicines. The invention provides an application of Ago2 in preparation of a medicine for treating fatty liver, and provides a medicine for treating fatty liver or hyperlipidemia and a preparation method thereof based on the new application of Ago2, and a protein, a gene, a recombinant expression vector and a transformant with the effect of treating fatty liver or hyperlipidemia. Animal experiments prove that the Ago2-based medicine for resisting fatty liver or hyperlipemia can remarkably reduce the liver lipid and blood fat content of animals with fatty liver caused by high fat, and the effective effect of resisting fatty liver or hyperlipemia is achieved.

The present invention relates to the field of biotechnology. The present invention relates to a bioactive polypeptide, which has the effect of protecting the liver. Specifically, the present invention provides a bioactive polypeptide molecule PGPIP derived from A2β-casein in cow's milk, and its amino acid sequence is Pro-Gly-Pro-Ile-Pro. The present invention has confirmed through in vitro and in vivo experiments that it can effectively reduce liver lipid accumulation and hepatocyte damage, providing a feasible direction for the treatment of liver diseases, especially the prevention and treatment of alcoholic fatty liver; this bioactive polypeptide also has great application potential in the fields of food and health products.

The invention discloses an application of a SUMO agonist N106 (the molecular formula is C17H14N4O3S, and the molecular weight is 354.38) in treatment or prevention of metabolic dysfunction related fatty liver disease (MASLD). The early-stage research of the invention finds that the liver SUMOylation level in MASLD clinical specimens and animal models is significantly reduced. In-vivo experiments show that in a high-fat diet induced C57BL / 6 mouse model, N106 (10mg / kg, intraperitoneal injection, once a day) can significantly improve liver lipid deposition and blood fat level of a high-fat diet mouse; in in-vitro experiments, N106 (10 mu M for 24 hours) can effectively reduce lipid droplet accumulation of HepG2 cells. The research reveals that N106 regulates lipid metabolism by activating an SUMOylation modification pathway for the first time, and a novel treatment strategy is provided for MASLD.

The invention discloses application of auricularia auricula monomer polysaccharide ME-2 in preparation of drugs for preventing and treating fatty liver diseases related to metabolic dysfunction. The research of the invention systematically proves that ME-2 has a remarkable intervention effect on the whole course of MASLD for the first time. The invention discloses a breakthrough function of ME-2 as a liver metabolism regulator for the first time: by directly correcting liver lipid metabolism disorder (such as regulating core genes such as Srebp-1c, ACC1, FASN and the like), liver fatty degeneration can be relieved in a dose-dependent manner in the whole course of MASLD, and the serum transaminase level and dyslipidemia can be reduced. Importantly, the curative effect of the traditional Chinese medicine is derived from intervention on a metabolic root source, and is totally different from a known anti-inflammatory application mechanism. Meanwhile, ME-2 has the remarkable advantages of being clear in structure, taking metabolic regulation as a core, and being safe and non-toxic, and a brand new drug candidate is provided for prevention and treatment of MASLD.

The present invention belongs to the field of biomedical technology, and specifically relates to the application of an antifreeze protein in weight loss and blood glucose reduction. The present invention successfully constructs an NPAFP transgenic mouse model by using genetic engineering technology, and verifies the potential application value of the NPAFP protein in weight loss and blood glucose reduction. Further, based on this model, it is found that the NPAFP protein has a significant effect on reducing fat accumulation and improving blood glucose levels by regulating brown fat metabolism and liver lipid droplet content. The development of compounds or protein engineering modification based on the NPAFP protein of the present invention can provide new drugs and strategies for the treatment of obesity and diabetes. At the same time, further exploring the molecular mechanism of the NPAFP protein by combining multi-omics technologies helps to promote its clinical translation and application.

The invention provides an application of a rhododendron dauricum extract in treating fatty liver diseases related to metabolic dysfunction. The folium rhododendri daurici extract is obtained by ultrasonic extraction of folium rhododendri daurici powder with an 80% ethanol solution as a solvent and is used for treating a hepatocyte lipid accumulation model and a metabolic dysfunction fatty liver disease mouse model. Experimental results show that the folium rhododendri daurici extract can inhibit lipid accumulation in HepG2 cells, relieve liver lipid accumulation of mice with metabolic dysfunction and fatty liver diseases, reduce TC, TG, AST and ALT levels of serum, reduce MDA expression in the serum, increase GSH expression in liver tissues, relieve liver injury and improve the antioxidant capacity of the mice. Therefore, the folium rhododendri daurici extract has a definite effect in the aspect of treating the metabolic dysfunction fatty liver disease, is simple in extraction process and small in toxic and side effects, and has a wide application prospect.

The invention belongs to the technical field of functional foods and health-care foods, and particularly relates to a composition with an effect of preventing and / or improving non-alcoholic fatty liver and a preparation method of the composition. The composition comprises an eggshell membrane extract, lemon concentrated powder, ganoderma sinensis powder and beet root powder. The composition prepared by the invention can be used for effectively relieving liver injury, liver lipid metabolism disorder and liver oxidative stress by reducing the liver index and weight change rate of a mouse, reducing the contents of AST and ALT in serum of the mouse and the contents of TC, TG and MDA in the liver and improving the content of SOD in the liver, so that the effect of improving the non-alcoholic fatty liver is achieved.